DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
August 15, 2024 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
August 15, 2024 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
August 15, 2024 07:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for...
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
August 15, 2024 07:00 ET
|
Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024 04:30 ET
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
August 15, 2024 04:30 ET
|
Alvotech
Markaðsleyfi fyrir Evrópu gæti verið veitt á þriðja fjórðungi næsta árs Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Advanz Pharma tilkynntu í dag að Lyfjastofnun...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
August 15, 2024 04:30 ET
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Celebrating Second Chances for National Tattoo Removal Day
August 14, 2024 18:02 ET
|
Astanza Laser
Dallas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- In a world where self-expression is paramount, National Tattoo Removal Day, observed annually on August 14th, shines a spotlight on the evolving landscape...
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024 16:53 ET
|
SciSparc Ltd
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its...
XWELL, Inc. Reports Second Quarter 2024 Results
August 14, 2024 16:30 ET
|
XWELL, Inc.
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the second...